CABA Cabaletta Bio Forecast, Technical & Fundamental Analysis
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases... Show more
CABA is expected to report earnings to fall 4.38% to -37 cents per share on August 06
Q2'26
Est.
$-0.37
Q1'26
Est.
$-0.39
Q4'25
Beat
by $0.06
Q3'25
Beat
by $0.03
Q2'25
Missed
by $0.08
The last earnings report on May 14 showed earnings per share of -38 cents, meeting the estimate of -38 cents. With 2.74M shares outstanding, the current market capitalization sits at 450.85M.
A.I. Advisor
published General Information
General Information
a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases
A.I.dvisor indicates that over the last year, CABA has been loosely correlated with PRME. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CABA jumps, then PRME could also see price increases.
CABA in +0.83% Uptrend, advancing for three consecutive days on June 24, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CABA advanced for three days, in of 250 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CABA's RSI Oscillator exited the oversold zone, of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 26, 2026. You may want to consider a long position or call options on CABA as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CABA just turned positive on June 29, 2026. Looking at past instances where CABA's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
CABA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 61 cases where CABA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
CABA moved below its 50-day moving average on June 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CABA crossed bearishly below the 50-day moving average on June 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CABA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CABA entered a downward trend on June 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.365) is normal, around the industry mean (22.885). P/E Ratio (0.000) is within average values for comparable stocks, (37.796). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.508). CABA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (434.181).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CABA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CABA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Cabaletta Bio (CABA) stock Forecast, Price Targets and Analysts Predictions - Tickeron.com
